Enterprise Published a Consensus Summary Document on Vaccine-induced Sero-reactivity

HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians - Antibody-inducing vaccines are a major focus in the preventive HIV vaccine field.  Because the most common tests for HIV infection rely on detecting antibodies to HIV, they may also detect antibodies induced by a candidate HIV vaccine.  The detection of vaccine-induced antibodies to HIV by serological tests is most commonly referred to as vaccine-induced sero-reactivity (VISR).  VISR can be misinterpreted as a sign of HIV infection in a healthy study participant.  In a participant who has developed vaccine-induced antibodies, accurate diagnosis of HIV infection (or lack thereof) may require specialized tests and algorithms (differential testing) that are usually not available in community settings.  Read more.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account